RVP 001
Alternative Names: Mn-PyC3A; RVP-001Latest Information Update: 27 Mar 2024
Price :
$50 *
At a glance
- Originator Harvard Medical School; Massachusetts General Hospital
- Developer Reveal Pharmaceuticals
- Class Antineoplastics; Contrast media; Imaging agents
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II CNS disorders
- Phase I Cancer
Most Recent Events
- 21 Mar 2024 Phase-II clinical trials in CNS disorders (Diagnosis) in USA (IV) (NCT06322342)
- 22 Aug 2022 Reveal Pharmaceuticals completes a phase I trial in Cancer (Diagnosis, In volunteers) in USA (IV) (NCT05413668)
- 23 Jun 2022 Reveal Pharmaceutical receives SBIR grant from National Cancer Institute for RVP 001 development in diagnosis of Cancer